Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 6/2017

01-11-2017 | Original Article

PRKAG2 mutations presenting in infancy

Authors: Rachel D. Torok, Stephanie L. Austin, Chanika Phornphutkul, Kathleen M. Rotondo, Deeksha Bali, Gregory H. Tatum, Stephanie B. Wechsler, Anne F. Buckley, Priya S. Kishnani

Published in: Journal of Inherited Metabolic Disease | Issue 6/2017

Login to get access

Abstract

PRKAG2 encodes the γ2 subunit of AMP-activated protein kinase (AMPK), which is an important regulator of cardiac metabolism. Mutations in PRKAG2 cause a cardiac syndrome comprising ventricular hypertrophy, pre-excitation, and progressive conduction-system disease, which is typically not diagnosed until adolescence or young adulthood. However, significant variability exists in the presentation and outcomes of patients with PRKAG2 mutations, with presentation in infancy being underrecognized. The diagnosis of PRKAG2 can be challenging in infants, and we describe our experience with three patients who were initially suspected to have Pompe disease yet ultimately diagnosed with mutations in PRKAG2. A disease-causing PRKAG2 mutation was identified in each case, with a novel missense mutation described in one patient. We highlight the potential for patients with PRKAG2 mutations to mimic Pompe disease in infancy and the need for confirmatory testing when diagnosing Pompe disease.
Literature
go back to reference Akman HO et al (2007) Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase. Pediatr Res 62(4):499–504CrossRefPubMed Akman HO et al (2007) Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase. Pediatr Res 62(4):499–504CrossRefPubMed
go back to reference Arad M et al (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109(3):357–362CrossRefPubMedPubMedCentral Arad M et al (2002) Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109(3):357–362CrossRefPubMedPubMedCentral
go back to reference Arad M et al (2003) Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107(22):2850–2856CrossRefPubMed Arad M et al (2003) Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107(22):2850–2856CrossRefPubMed
go back to reference Austin SL et al (2017) Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Mol Genet Metab 120(1–2):96–100CrossRefPubMed Austin SL et al (2017) Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation. Mol Genet Metab 120(1–2):96–100CrossRefPubMed
go back to reference Blair E et al (2001) Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10(11):1215–1220CrossRefPubMed Blair E et al (2001) Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 10(11):1215–1220CrossRefPubMed
go back to reference Bobele GB et al (1993) Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 147(2):223–225CrossRefPubMed Bobele GB et al (1993) Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 147(2):223–225CrossRefPubMed
go back to reference Burwinkel B et al (2005) Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 76(6):1034–1049CrossRefPubMedPubMedCentral Burwinkel B et al (2005) Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 76(6):1034–1049CrossRefPubMedPubMedCentral
go back to reference de Vries JM et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73CrossRefPubMedPubMedCentral de Vries JM et al (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73CrossRefPubMedPubMedCentral
go back to reference Doyle LW, et al (2014) Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (5): CD001146 Doyle LW, et al (2014) Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (5): CD001146
go back to reference Fu L et al (2016) Identification of LAMP2 mutations in early-onset Danon disease with hypertrophic cardiomyopathy by targeted next-generation sequencing. Am J Cardiol 118(6):888–894CrossRefPubMed Fu L et al (2016) Identification of LAMP2 mutations in early-onset Danon disease with hypertrophic cardiomyopathy by targeted next-generation sequencing. Am J Cardiol 118(6):888–894CrossRefPubMed
go back to reference Gollob MH (2008) Modulating phenotypic expression of the PRKAG2 cardiac syndrome. Circulation 117(2):134–135CrossRefPubMed Gollob MH (2008) Modulating phenotypic expression of the PRKAG2 cardiac syndrome. Circulation 117(2):134–135CrossRefPubMed
go back to reference Gollob MH et al (2001) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344(24):1823–1831CrossRefPubMed Gollob MH et al (2001) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344(24):1823–1831CrossRefPubMed
go back to reference Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular pre-excitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17(3):229–234CrossRefPubMed Gollob MH et al (2002) PRKAG2 cardiac syndrome: familial ventricular pre-excitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17(3):229–234CrossRefPubMed
go back to reference Hamdan MA et al (2010) Antenatal diagnosis of pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy. J Inherit Metab Dis 33(Suppl 3):S333–S339CrossRefPubMed Hamdan MA et al (2010) Antenatal diagnosis of pompe disease by fetal echocardiography: impact on outcome after early initiation of enzyme replacement therapy. J Inherit Metab Dis 33(Suppl 3):S333–S339CrossRefPubMed
go back to reference Hardie DG (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144(12):5179–5183CrossRefPubMed Hardie DG (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144(12):5179–5183CrossRefPubMed
go back to reference Huie ML et al (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet 3(12):2231–2236CrossRefPubMed Huie ML et al (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet 3(12):2231–2236CrossRefPubMed
go back to reference Kelly BP et al (2009) Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation. Pediatr Cardiol 30(8):1176–1179CrossRefPubMed Kelly BP et al (2009) Severe hypertrophic cardiomyopathy in an infant with a novel PRKAG2 gene mutation: potential differences between infantile and adult onset presentation. Pediatr Cardiol 30(8):1176–1179CrossRefPubMed
go back to reference Kemp BE et al (1999) Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 24(1):22–25CrossRefPubMed Kemp BE et al (1999) Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 24(1):22–25CrossRefPubMed
go back to reference Kim M et al (2014) Mutation in the gamma2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 114(6):966–975CrossRefPubMedPubMedCentral Kim M et al (2014) Mutation in the gamma2-subunit of AMP-activated protein kinase stimulates cardiomyocyte proliferation and hypertrophy independent of glycogen storage. Circ Res 114(6):966–975CrossRefPubMedPubMedCentral
go back to reference Kishnani PS et al (2014) Methods of diagnosis of patients with Pompe disease: data from the Pompe registry. Mol Genet Metab 113(1–2):84–91CrossRefPubMed Kishnani PS et al (2014) Methods of diagnosis of patients with Pompe disease: data from the Pompe registry. Mol Genet Metab 113(1–2):84–91CrossRefPubMed
go back to reference Laforet P et al (2006) A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 16(3):178–182CrossRefPubMed Laforet P et al (2006) A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 16(3):178–182CrossRefPubMed
go back to reference MacRae CA et al (1995) Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 96(3):1216–1220CrossRefPubMedPubMedCentral MacRae CA et al (1995) Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest 96(3):1216–1220CrossRefPubMedPubMedCentral
go back to reference Murphy RT et al (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45(6):922–930CrossRefPubMed Murphy RT et al (2005) Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 45(6):922–930CrossRefPubMed
go back to reference Xu Y, et al (2017) A novel, de novo mutation in PRKAG2 gene: infantile-onset phenotype and signaling pathway involved. Am J Physiol Heart Circ Physiol: ajpheart 00813 02016 Xu Y, et al (2017) A novel, de novo mutation in PRKAG2 gene: infantile-onset phenotype and signaling pathway involved. Am J Physiol Heart Circ Physiol: ajpheart 00813 02016
Metadata
Title
PRKAG2 mutations presenting in infancy
Authors
Rachel D. Torok
Stephanie L. Austin
Chanika Phornphutkul
Kathleen M. Rotondo
Deeksha Bali
Gregory H. Tatum
Stephanie B. Wechsler
Anne F. Buckley
Priya S. Kishnani
Publication date
01-11-2017
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 6/2017
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-017-0072-0

Other articles of this Issue 6/2017

Journal of Inherited Metabolic Disease 6/2017 Go to the issue

Highlights

News and views

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.